We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 15 maart 2017

The Lancet: [News] Blinatumomab significantly improves overall survival

[News] Blinatumomab significantly improves overall survival
The monoclonal antibody blinatumomab significantly improves overall survival in adults with heavily pretreated B-cell precursor acute lymphoblastic leukaemia (ALL), according to a new study. In the phase 3 trial, patients with Philadelphia chromosome–negative, relapsed, or refractory B-cell precursor ALL were randomly assigned to receive either blinatumomab (n=267) or standard-of-care chemotherapy (n=109). At the pre-planned interim analysis, median overall survival (the primary endpoint) was 7·7 months (95% CI 5·6–9·6) in the blinatumomab group and 4·0 months (2·9–5·3) in the chemotherapy group (hazard ratio 0·71 [0·55–0·93]; p=0·01).
Read more

[Articles] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Pembrolizumab appears to be well tolerated and might confer anti-tumour activity in patients with PD-L1-positive malignant pleural mesothelioma. Response durability and efficacy in this patient population warrants further investigation.
Read more

[Comment] SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?
Since the regulatory approval of tamoxifen in 1977, treatment with endocrine monotherapy, including aromatase inhibitors such as exemestane, has been the foundation of treatment for hormone receptor-positive metastatic breast cancer.1 However, in 2012, the approval of the mTOR inhibitor everolimus combined with exemestane,2 based on a randomised phase 3 study (BOLERO-2)3,4 showing that the addition of everolimus to exemestane (vs exemestane alone) extended median progression-free survival from 4·1 months to 11·0 months (log-rank p<0·0001), represented a crucial shift in the treatment landscape for hormone receptor-positive metastatic breast cancer.
Read more

[Comment] Immune-checkpoint inhibition for digestive cancers
Oesophageal cancer, squamous-cell carcinoma, or adenocarcinoma, are frequently diagnosed at advanced stages and have poor prognosis. Despite decreasing incidence in squamous-cell carcinoma in many countries, the incidence of oesophageal cancer has not changed over time due to a rise in incidence of adenocarcinoma.1 Thus, oesophageal cancer remains the eighth most frequent cancer and the sixth most common cause of death from cancer worldwide.1
Read more

[Articles] Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Nivolumab showed promising activity with a manageable safety profile. This drug could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma.
Read more